Please note: The Research + Innovation office will be closed for the holidays from noon on December 24 through January 2nd, inclusive. 鉂勶笍 Veuillez noter que le bureau de la Recherche et de l'Innovation sera ferm茅 pour les vacances du 24听d茅cembre 脿 midi jusqu鈥檃u 2听janvier inclus.
News
A fully soluble ubiquinone formulation for mitochondrial diseases
Published: 10 October 2019
Invention 2018-049
A fully soluble ubiquinone formulation for mitochondrial diseases
听
A new formulation of ubiquinone that will improve delivery efficiency for supplementation in mitochondrial diseases has been developed at 捆绑SM社区.
听
Market Need
In the mitochondria, the electron transport chain produces the molecule responsible for driving most of the body鈥檚 enzymatic reactions: ATP. An integral molecule in this process is the lipid ubiquinone. A deficiency in ubiquinone is commonly associated as being a factor in heart diseases, fetal mitochondrial diseases, and Parkinson鈥檚 disease. Unfortunately, the currently available formulations are not very effective because they are very hydrophobic and essentially insoluble in aqueous solutions. Therefore, very little of the administered ubiquinone reaches the organs that need the molecule for the synthesis of ATP.
听
Technology Summary
In this invention, a new formulation of ubiquinone was developed using only non-toxic and FDA-approved components. Since this improved form of ubiquinone is a fully soluble molecule that can be administered in a variety of ways, it will be able to reach the organs affected by mitochondrial diseases: the heart, muscles, kidney, and brain. A proof of concept was verified in animal models of ubiquinone deficiency, while mitochondrial disease models are underway.
听
Advantages
- Fully soluble ubiquinone that successfully reaches mitochondria in target organs
- Successful administration in ubiquinone deficiency animal models
听
Patent Status
Filed PCT